Resource Category: Publications

Structure-Activity Relationship and Biological Investigation of a REV-ERBα-Selective Agonist SR-29065 (34) for Autoimmune Disorders

Di Zhu, Qun Lu, Yuanjun He et al. J Med Chem. 2023 Nov 9;66(21):14815-14823. doi: 10.1021/acs.jmedchem.3c01413. Epub 2023 Oct 27.

November 9, 2023

Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models

Miao Jiang, Fubo Yang, Yajuan Jiang, Lihua Cheng, Jing Han, Jing Yi, Guangwei Zhang, Zhihua Ma, Liying Cao, Bin Zuo, Lixiang Zhou, Lihui Huang, Shuhua Niu, Zhiyong Xia, Xiaoping Zhou, Xiaohui Bai, Nancy L Esmon, Cangping Xia, Lihong Han, Cheng

September 21, 2023

Development of high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma

Yu Rebecca Miao et al. J Exp Med. 2022 Sep 5;219(9):e20220214. doi: 10.1084/jem.20220214. Epub 2022 Jul 26.

June 21, 2023

Characterization of 405B8H3(D-E), a newly engineered high affinity chimeric LAG-3 antibody with potent antitumor activity

Lan X, et al. FEBS Open Bio. 2023 Jul;13(7):1253-1265. doi: 10.1002/2211-5463.13648. Epub 2023 Jun 11.

June 11, 2023

Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates

Yingying Gao, Hongliang Li, Ning Su, Tianyi Yang, Chen Dong, Yanhong Dong. Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates. FEBS Open Bio. 2022 Dec;12(12):2166-2178. doi: 10.1002/2211-5463.13494.

October 9, 2022

A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo

Suchowerska AK, Parmar J, Lambert G, Palmer JT, Treutlein H, Zeng J, Nativel B, Chemello K, Zhu Q, Wang J, Teng Y, Tang W, Xu Y, Rathi AK, Kumar S, Evison BJ. J Lipid Res. 2022 Nov;63(11):100293.

October 6, 2022

Development of a fully human anti-GITR antibody with potent antitumor activity using H2L2 mice

Tong Q, Yu T, Li H, Qian Q, Ding C. Development of a fully human anti-GITR antibody with potent antitumor activity using H2L2 mice. FEBS Open Bio. 2022 Aug;12(8):1542-1557. doi: 10.1002/2211-5463.13451. Epub 2022 Jun 21.

June 21, 2022

Methods to assess small molecule allosteric modulators of the STRAD pseudokinase

Tingting Qing, John D Gordan. Methods Enzymol. 2022:667:427-453. doi: 10.1016/bs.mie.2022.03.041. Epub 2022 Apr 13.

April 13, 2022

Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies

Chen Y, Nagaraja NV, Fan B, Uehling L, Linton RM, Perez-Moreno JP, Dutta L, Kim H, Song SS-M, Borthakur SA, Yang H, et al. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1

October 21, 2021

Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer

Xu Y, Wei B, et al. Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer. Clin Cancer Res. 2021 Aug 1;27(15):4435-4448. doi: 10.1158/1078-0432.CCR-20-0482. Epub 2021 May 19.

August 1, 2021